Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer.
CTC
EMT
NMIBC
PD-L1
RFS
TIMP2
TWIST1
immunotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Nov 2021
28 Nov 2021
Historique:
received:
16
11
2021
accepted:
24
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
PD-L1 represents a crucial immune checkpoint molecule in the tumor microenvironment, identified as a key target for cancer immunotherapy. A correlation between By ScreenCell filtration, digital droplet PCR and confocal microscopy analysis, we aimed to investigate the expression of Higher High
Sections du résumé
BACKGROUND
BACKGROUND
PD-L1 represents a crucial immune checkpoint molecule in the tumor microenvironment, identified as a key target for cancer immunotherapy. A correlation between
METHODS
METHODS
By ScreenCell filtration, digital droplet PCR and confocal microscopy analysis, we aimed to investigate the expression of
RESULTS
RESULTS
Higher
CONCLUSIONS
CONCLUSIONS
High
Identifiants
pubmed: 34885101
pii: cancers13235989
doi: 10.3390/cancers13235989
pmc: PMC8656875
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero dell'Università e della Ricerca
ID : Prin 2017
Organisme : Fondazione Umberto Veronesi
ID : Post-doctoral fellowship 2018-2019
Références
Cancer Immunol Immunother. 2018 Mar;67(3):403-412
pubmed: 29150702
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Mol Histol. 2021 Jun;52(3):597-609
pubmed: 33884540
Mol Cancer. 2015 Aug 07;14:149
pubmed: 26245467
World J Urol. 2016 May;34(5):709-16
pubmed: 26394624
Clin Cancer Res. 2021 Nov 15;27(22):6265-6278
pubmed: 34526362
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Biochim Biophys Acta Mol Basis Dis. 2022 Jan 1;1868(1):166271
pubmed: 34562599
Oncogene. 2015 Oct;34(43):5447-59
pubmed: 25684140
J Urol. 2001 May;165(5):1769-72
pubmed: 11342973
PLoS One. 2021 Jul 9;16(7):e0254433
pubmed: 34242363
BMC Urol. 2018 Nov 6;18(1):97
pubmed: 30400941
Hum Pathol. 2015 Sep;46(9):1267-74
pubmed: 26170011
BMC Cancer. 2016 Sep 22;16(1):744
pubmed: 27658492
Eur J Surg Oncol. 2014 Jan;40(1):121-7
pubmed: 24140000
Urol Oncol. 2015 Mar;33(3):110.e11-8
pubmed: 25262382
Support Care Cancer. 2013 May;21(5):1383-93
pubmed: 23238655
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Clin Genitourin Cancer. 2017 Aug;15(4):e661-e666
pubmed: 28188046
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
World J Urol. 2020 Oct;38(10):2537-2545
pubmed: 31900581
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Int J Cancer. 2014 Oct 15;135(8):1978-82
pubmed: 24599551
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
BMC Cancer. 2011 Aug 04;11:336
pubmed: 21816094
Front Oncol. 2018 Sep 07;8:362
pubmed: 30245975
Cancer Sci. 2017 Jun;108(6):1119-1127
pubmed: 28294486
Int J Cancer. 2017 Jan 15;140(2):381-389
pubmed: 27668704
Oncotarget. 2016 Mar 29;7(13):15901-14
pubmed: 26893364
Urology. 2018 May;115:82-86
pubmed: 29432873
Anal Cell Pathol (Amst). 2018 Mar 7;2018:9718585
pubmed: 29707475